Skip Navigation LinksHome > March 2014 - Volume 32 - Issue 3 > Actions of rilmenidine on neurogenic hypertension in BPH/2J...
Journal of Hypertension:
doi: 10.1097/HJH.0000000000000036
ORIGINAL PAPERS: Neurogenic mechanisms

Actions of rilmenidine on neurogenic hypertension in BPH/2J genetically hypertensive mice

Jackson, Kristy L.a,b; Palma-Rigo, Kesiaa; Nguyen-Huu, Thu-Phuca; Davern, Pamela J.a,*; Head, Geoffrey A.a,b,*

Supplemental Author Material
Collapse Box


Objective: BPH/2J hypertensive mice have an exaggerated sympathetic contribution to blood pressure (BP). Premotor sympathetic neurons within the rostroventrolateral medulla (RVLM) are a major source of sympathetic vasomotor tone and major site of action of the centrally acting sympatholytic agent, rilmenidine. The relative cardiovascular effect of rilmenidine in BPH/2J versus normotensive BPN/3J mice was used as an indicator of the involvement of the RVLM in the sympathetic contribution to hypertension in BPH/2J mice.

Methods: BPH/2J and BPN/3J mice were pre-implanted with telemetry devices to measure BP in conscious unrestrained mice. Rilmenidine was administered acutely (n = 7–9/group), orally for 14 days, at a wide range of doses (n = 5/group), and also infused intracerebroventricularly for 7 days (n = 6/group).

Results: Acute intraperitoneal rilmenidine induced greater depressor and bradycardic responses in BPH/2J than BPN/3J mice (Pstrain < 0.01). Both responses were reduced by atropine pre-treatment, with the remaining hypotensive effect being small and comparable between strains (Pstrain = 1.0). This suggests that vagally induced reductions in cardiac output were responsible for the hypotension. Chronic intracerebroventricularly infused rilmenidine reduced BP from baseline marginally in BPH/2J mice during the dark (active) period (−6.5 ± 2 mmHg; P= 0.006). Chronic orally administered rilmenidine (1–12 mg/kg per day) also had minimal effect on 24-h BP in both strains (P > 0.16).

Conclusion: The sympathetic vasomotor inhibitory effect of rilmenidine is minimal in both strains and similar in hypertensive BPH/2J and BPN/3J mice. Thus, hypertension in BPH/2J mice is not likely mediated by greater neuronal activity in the RVLM, and agents such as rilmenidine would be an ineffective treatment for this form of neurogenic hypertension.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.